Literature DB >> 10371662

Effects of antidepressants in rats trained to discriminate the beta-2 adrenergic agonist clenbuterol.

M M Makhay1, J M O'Donnell.   

Abstract

The ability of indirectly acting agonists such as norepinephrine uptake inhibitors, serotonin reuptake inhibitors, and atypical antidepressants to substitute for clenbuterol, a beta-2 adrenergic agonist, was examined in rats trained to discriminate 0.03 mg/kg clenbuterol and saline using a fixed-ratio 10 (FR 10) schedule with water reinforcement. The beta-2 selective adrenergic agonist clenbuterol produced an orderly dose-response relationship, and its discriminative stimulus effects were antagonized by the beta-adrenergic antagonist propranolol. It was found that the effects of tricyclic antidepressants and selective norepinephrine uptake inhibitors did not generalize to the discriminative stimulus effects of clenbuterol, with the exception of high doses of protriptyline. Moreover, compounds from other drug classes, including fluoxetine and phenelzine, did not substitute for clenbuterol. Atypical antidepressants, such as trazodone, rolipram, and bupropion also did not engender drug-appropriate responding. Prenalterol and dobutamine, both purported to be beta-1 adrenergic receptor agonists, partially substituted for clenbuterol, but at relatively high doses. The present results show that the antidepressants tested do not share discriminative stimulus effects with clenbuterol, a beta-2 adrenergic agonist.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10371662     DOI: 10.1016/s0091-3057(98)00266-4

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  5 in total

1.  Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats.

Authors:  Han-Ting Zhang; Ying Huang; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

Review 2.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

3.  On the improvement of inhibitory response control and visuospatial attention by indirect and direct adrenoceptor agonists.

Authors:  Tommy Pattij; Dustin Schetters; Anton N M Schoffelmeer; Marcel M van Gaalen
Journal:  Psychopharmacology (Berl)       Date:  2011-07-19       Impact factor: 4.530

4.  Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation.

Authors:  F Ivy Carroll; Bruce E Blough; S Wayne Mascarella; Hernán A Navarro; J Brek Eaton; Ronald J Lukas; M Imad Damaj
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

Review 5.  Mechanistic insights into nicotine withdrawal.

Authors:  Michael Paolini; Mariella De Biasi
Journal:  Biochem Pharmacol       Date:  2011-07-20       Impact factor: 5.858

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.